Italia markets closed

ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,5500+0,0400 (+1,59%)
Alla chiusura: 04:00PM EDT
2,5200 -0,03 (-1,18%)
Dopo ore: 06:56PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,5100
Aperto2,4700
Denaro2,4500 x 4000
Lettera2,5400 x 3200
Min-Max giorno2,4700 - 2,6450
Intervallo di 52 settimane1,0100 - 2,6450
Volume3.284.902
Media Volume2.627.766
Capitalizzazione500,71M
Beta (5 anni mensile)1,02
Rapporto PE (ttm)N/D
EPS (ttm)-0,4900
Prossima data utili08 nov 2022 - 14 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A4,67
  • GlobeNewswire

    ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

    2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA)

  • GlobeNewswire

    ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022

    Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, after the U.S. financial markets clos

  • GlobeNewswire

    ADMA Biologics Announces Addition to the Russell 2000® Index

    Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022. The Russell 2000® Ind